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Abstract
Introduction: Memantine and cholinesterase inhibitors potentially offer additional benefits in Alzheimer’s disease
(AD) when used together. This study assessed the efficacy and safety of combination treatment with memantine
added to stable donepezil in patients with moderate to severe AD, and in a subset with moderate AD.
Methods: Post hoc meta-analyses of data combined from two 24-week, randomised, double-blind, placebo-
controlled trials of memantine 20 mg/day versus placebo, added to a stable cholinesterase inhibitor, were
conducted. Data were included for all patients receiving donepezil 10 mg/day with Mini-Mental State Examination
(MMSE) scores < 20 (n = 510). Efficacy was assessed using measures of cognition, function, and global status.
Furthermore, marked clinical worsening, defined as concurrent deterioration from baseline in the three main
efficacy domains, and safety, measured by treatment-emergent adverse events, were assessed. Analyses were
performed for patients with moderate to severe AD (MMSE 5-19; MOD-SEV subgroup), and also for patients with
moderate AD (MMSE 10-19; MOD subgroup; n = 367).
Results: At week 24, in the MOD-SEV subgroup, patients receiving memantine added to donepezil significantly
outperformed those receiving placebo added to donepezil in measures of cognition (P < 0.0001), function (P =0 . 0 2 ) ,
and global status (P = 0.010), with standardised mean differences (SMDs) of 0.36, 0.21, and 0.23, respectively (all last
observation carried forward). Similarly, in the MOD subgroup, significant benefits were observed for cognition (P =
0.008), function (P = 0.04) and global status (P = 0.008), with SMDs of 0.28, 0.21, and 0.28, respectively. Significantly fewer
patients receiving memantine added to donepezil showed marked clinical worsening than those receiving placebo
added to donepezil, in both subgroups (MOD-SEV: 8.7% versus 20.4%, P = 0.0002; MOD: 5.9% versus 15.0%, P = 0.006).
The incidence of adverse events was similar between treatment groups.
Conclusions: These results support and extend previous evidence that combination treatment with memantine
added to stable donepezil in patients with moderate AD, and in those with moderate to severe AD, is associated
with significant benefits in reducing 24-week decline in cognition, function and global status. Combination
treatment produces substantially reduced rates of marked clinical worsening, has good safety and tolerability, and
generates effect sizes that are both statistically significant and clinically meaningful.
Introduction
Alzheimer’s disease (AD) is a progressive neurodegenera-
tive disorder in which patients typically lose cognitive
faculties, struggle to carry out activities of daily living
(ADLs), and experience behavioural and neuropsychiatric
problems. At present, AD cannot be cured, any improve-
ments produced by pharmacotherapy are often tempor-
ary, and no treatments have been demonstrated to be
disease-modifying. Consequently, alleviating symptoms,
and delaying or reducing clinical worsening (that is,
symptom progression), without modifying the underlying
pathophysiology, are realistic and meaningful treatment
goals [1] that can be termed disease-course-modifying
effects [2]. Achieving these goals allows patients to spend
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than they would without treatment [1].
Memantine, an uncompetitive antagonist of N-methyl-
D-aspartate (NMDA) glutamate receptors, is approved
in the EU and US for the treatment of patients with
moderate to severe AD (Mini-Mental State Examination
[MMSE] [3] score < 20). Donepezil, a cholinesterase
inhibitor (ChEI), is approved for the treatment of mild
to moderate AD in the EU, and for mild, moderate, and
severe AD in the US and some other countries. As
monotherapy, both memantine and donepezil have
demonstrated efficacy for treating the symptoms of AD
within their respective approved indications [4-12]. In
addition, the incidence of clinical worsening, as defined
by concurrent deterioration in three domains (cognitive,
functional, and global) over time, is reduced by meman-
tine treatment in patients with moderate to severe AD
[6], and by donepezil treatment in patients with mild to
moderate AD [13].
Since memantine and donepezil have different and
complementary mechanisms of action, together they
potentially offer additional benefits to the patient [14].
Pharmacokinetic and pharmacodynamic data in healthy
volunteers provided initial evidence that memantine and
donepezil may be safely used in combination [15]. The
addition of memantine to stable ChEI therapy has also
been associated with a good safety profile in patients
with AD [16,17].
Two 24-week, randomised, double-blind, placebo-con-
t r o l l e dt r i a l s( R C T s )h a v ei n v estigated the efficacy and
safety of memantine 20 mg/day in combination with a
ChEI. The first, MEM-MD-02, assessed the efficacy of
administration of memantine (10 mg twice daily) versus
placebo in patients with moderate to severe AD (MMSE
5-14; n = 404) receiving stable donepezil therapy [16].
Relative to placebo, memantine produced significant bene-
fits in all four key symptom domains of AD, namely, cog-
nition, function, behaviour, and global status [16]. The
second RCT, MEM-MD-12, assessed the efficacy of
administration of memantine (20 mg once daily) versus
placebo in patients with mild to moderate AD (MMSE
10-22; n = 433) taking a stable dose of any approved ChEI
therapy [17]. In this trial, the only potential signal of bene-
fit for memantine treatment over placebo (effect size esti-
mate 0.118 in favour of memantine; P =0 . 1 8 4 )w a s
observed for the cognitive measure (AD Assessment
Scale-cognitive subscale, ADAS-Cog), but the trial was not
adequately powered to detect with statistical significance,
an effect size smaller than 0.325 [17]. In both studies,
combination therapy with memantine added to a ChEI
was well-tolerated [16,17].
In addition to the lack of power to detect effect sizes
smaller than 0.325, two possible explanations were pro-
vided by Porsteinsson and colleagues for the discrepancy
in findings between MEM-MD-02 and MEM-MD-12: the
difference in baseline disease severity, and the difference
in permitted ChEIs [17]. In the present study, data from
both RCTs are combined, and the hypothesis that low
power and baseline heterogeneities caused the divergent
results between MEM-MD-02 and MEM-MD-12, and
potentially obscured significant memantine treatment-
related benefits in patients with moderate AD, is tested. In
a post hoc meta-analysis and subgroup analysis approach,
these data are used to assess the efficacy of memantine 20
mg/day versus placebo in patients receiving stable doses of
donepezil (10 mg/day) in two subgroups: moderate to
severe AD (MMSE 5 to 19), and moderate AD (MMSE 10
to 19).
The rationale for choosing these patient subgroups (sub-
populations) were that they represent the current
approved indication of memantine in the EU (moderate to
severe AD), and the overlap of the approved memantine
and donepezil indications in the EU (moderate AD). As is
commonly done in clinical trials, the MMSE was used as a
subpopulation staging surrogate measure to delineate mild
(MMSE ≥ 20) from moderate (MMSE 10 to 19) and severe
(MMSE < 10) stages of AD. Finally, since donepezil was
the most commonly used ChEI in these trials, ChEIs other
than donepezil were excluded, and analysis was restricted
to patients receiving 10 mg/day of donepezil to minimise
heterogeneity and any potential effects of underdosing.
Therefore, the analyses in this study of patients with AD
with MMSE < 20 taking stable donepezil 10 mg/day con-
sist of: 1) meta-analyses to compare the efficacy of mem-
antine versus placebo across individual domains of AD; 2)
pooled analyses to compare the efficacy of memantine
versus placebo in reducing the occurrence of marked clini-
cal worsening, and 3) pooled analyses to assess the toler-
ability profile of memantine versus placebo.
Methods
Study design and patients
Figure 1 depicts data flow for study inclusion and sub-
group analysis. Studies were selected for inclusion if they
fulfilled the criteria of: phase III RCTs of patients with a
diagnosis of AD and treated with memantine 20 mg/day
added to stable ChEI; a double-blind observation period of
at least 24 weeks, and a majority of patients receiving
stable treatment with donepezil. Two studies met the
inclusion criteria (MEM-MD-02 and MEM-MD-12), both
of which were performed in multiple centres in the US
[16,17]. Study approval was granted by the local Institu-
tional Review Board (IRB) at each trial site, and written
informed consent was obtained from each study partici-
pant if possible, and either the caregiver or a legally accep-
table representative (if different from the caregiver) before
initiation of study-specific procedures according to IRB
protocols [16,17].
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sion criteria for MEM-MD-02 and MEM-MD-12 have
been presented previously [16,17]. In summary, the
patient inclusion criteria were similar: 50 years of age or
older; diagnosis of probable AD according to the
NINCDS-ADRDA criteria; a brain magnetic resonance
imaging or computed tomographic scan within 12
months consistent with a diagnosis of probable AD; and
treatment with a ChEI for at least 6 months with a stable
dosing regimen for at least 3 months. The individual clin-
ical study inclusion criteria differed in the required base-
line MMSE score (see Figure 1) and the allowed ChEI
(only donepezil use in MEM-MD-02; any ChEI in MEM-
MD-12). In both studies, patients treated with meman-
tine received a fixed total dose of 20 mg/day.
Selection was restricted to patients receiving stable
treatment with donepezil 10 mg/day. Two subgroups of
patients were analysed: the MOD to SEV subgroup of
patients with moderate to severe AD (MMSE < 20,
range 5 to 19), conforming to the approved indication
of memantine in the EU, and the MOD subgroup of
patients with moderate AD (MMSE 10 to 19), conform-
ing to the overlap of the approved memantine and
donepezil indications in the EU.
Trial registration
The data were obtained from the sponsors of the origi-
nal trials; trial registration was not relevant to these two
studies since both studies were completed before July 1,
2005; MEM-MD-02 was completed by June 2002, and
MEM-MD-12 was completed by March 2003 [16,17].
Efficacy measures
Cognition was assessed using the Severe Impairment Bat-
tery (SIB) [18-20] in study MEM-MD-02 (patients with
moderate to severe AD) and the ADAS-Cog [21] in study
MEM-MD-12 (patients with mild to moderate AD). In
both studies, function was assessed using the AD Coopera-
tive Study - Activities of Daily Living scale (ADCS-ADL)
[22,23]. The 23-item version (ADCS-ADL23) was used in
Figure 1 Patient flow.
a5t o1 0m g / d a yf o r≥ 3m o n t h s .
b5 or 10 mg/day donepezil; 6, 9 or 12 mg/day rivastigmine; 16 or 24 mg/day
galantamine for ≥ 3 months. MMSE, Mini-Mental State Examination; ChEI, cholinesterase inhibitor; ITT, intention-to-treat; APT, all-patients-treated;
AD, Alzheimer’s disease.
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developed specifically for patients with moderate to severe
AD [23], was used in MEM-MD-02. Global status was
assessed using the Clinician’s Interview-Based Impression
of Change Plus Caregiver Input (CIBIC-Plus) [24,25].
An individual domains meta-analysis was performed for
each subgroup. This required data from the different cog-
nitive and functional rating scales within the same domain
to be combined across the selected trials. Consequently,
the outcome measures for this meta-analysis were change
from baseline to endpoint (week 24) in cognition (SIB/
ADAS-Cog score), function (ADCS-ADL19/ADCS-ADL23
score), and global status (CIBIC-Plus score).
Data from both studies were pooled in clinical worsen-
ing analyses, a form of responder analysis in which
response is defined not by improvement but by worsen-
ing [6]. The criteria used to define clinical worsening
were based on concurrent worsening in the cognitive,
functional and global domains from baseline to endpoint
(week 24) [6]. Marked clinical worsening was defined as a
decline of ≥ 4 points on ADAS-Cog or ≥ 5 points on SIB,
plus any decline on ADCS-ADL19/ADCS-ADL23 and
CIBIC-Plus [6]. This definition is intended to represent
the average natural cognitive decline observed in patients
with moderate to severe AD over 6 months, and can be
considered as clinically significant cognitive worsening
[6].
Finally, safety and tolerability were assessed in a
pooled analysis of adverse events (AEs), including both
the total incidence of AEs, and the AEs with an inci-
dence ≥ 5% in either treatment group.
Statistical analysis
All analyses were performed using SAS
® 9.2 and RevMan
5 software. Efficacy was analysed in the intention-to-treat
(ITT) set, defined as all patients who were randomised
to, and received at least one dose of, either placebo or
memantine, and who completed at least one post-base-
line assessment in the cognitive (SIB/ADAS-Cog) or
functional (ADCS-ADL19/23) domains. Analyses were
conducted at week 24 using the last observation carried
forward (LOCF) approach for missing data, and also for
observed cases (OC).
For the individual studies in the meta-analyses, standar-
dised effect sizes for each outcome measure were calculated
as the standardised mean difference (SMD) of the change
from baseline to endpoint. The overall standardised effect
size for each outcome measure was calculated using the
inverse-variance method. Per convention, we use Cohen’s
guidelines to serve as operational definitions to qualitatively
interpret the magnitude of effect sizes as follows: 0.2 is
small, 0.5 is medium, and 0.8 is large [26]. Effect sizes of
magnitude 0.2 or larger are considered clinically significant
in the context of general medical therapeutics [26], and are
also clinically noticeable in the context of AD therapeutics
[27]. The meta-analyses were conducted using the fixed-
effect model. Overall effect was tested using the Z-statistic.
Statistical testing for heterogeneity was based on chi
squared tests and the I-squared summary statistic; hetero-
geneity between studies was considered for P-values < 0.10,
or I-squared > 50%. The pooled analyses of clinical worsen-
ing included patients in the ITT set who had an assessment
on all three efficacy scales.
Safety was assessed in the all-patients-treated (APT)
set, defined as all patients who were randomised to, and
received at least one dose of, either placebo or meman-
tine. Significance was calculated using Fisher’s exact test;
P-values < 0.05 were considered statistically significant.
Results
Study population
A total of 510 patients with moderate to severe AD
(MOD-SEV subgroup; MMSE 5 to 19) (339 from MEM-
MD-02, and 171 from MEM-MD-12; 264 receiving mem-
antine added to donepezil, and 246 receiving placebo
added to donepezil) were included in the ITT set. Of
these, 367 patients (186 receiving memantine added to
donepezil, and 181 receiving placebo added to donepezil)
were part of the MOD subgroup (MMSE 10 to 19) (Figure
1). As expected, other than baseline MMSE score, there
were no clinically relevant differences between treatment
groups in terms of baseline demographics (Table 1).
Excluded patient population characteristics
Table 2 shows the baseline characteristics for the 327
patients (mean baseline MMSE 18.0) originally enrolled
in MEM-MD-02 (65 of 404 patients) or MEM-MD-12
(262 of 433 patients) who did not meet inclusion criteria
for this study and were excluded from the efficacy ana-
lysis. Of the excluded patients who were part of the ITT
set, 130 (all from MEM-MD-12; 90 receiving donepezil
and 40 receiving a ChEI other than donepezil) met
exclusion criteria for mild-stage AD (a baseline MMSE
score of ≥ 20); there were no significant differences in
baseline MMSE between patients randomised to mem-
antine (n = 63; MMSE = 21.1) or placebo (n =6 7 ;
MMSE = 21.0). A further 100 patients from the ITT set
(all from MEM-MD-12) met baseline MMSE criteria for
moderate AD (MMSE 10 to 19) but were excluded for
receiving a ChEI other than donepezil; these patients
also had no significant differences in baseline MMSE
between those randomised to memantine (n =4 7 ;
MMSE 14.1) or placebo (n = 53; MMSE 15.0). Finally,
81 patients from the ITT set (56 from MEM-MD-02
a n d2 5f r o mM E M - M D - 1 2 )w e r ee x c l u d e df o rt a k i n ga
dose of donepezil less than 10 mg/day.
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After 24 weeks of treatment, patients in the MOD-SEV
subgroup receiving memantine added to donepezil
showed significantly better efficacy across all examined
domains of cognition, function, and global status than
patients treated with placebo added to donepezil. The
overall standardised effect sizes for memantine versus
placebo were: 0.36 (P < 0.0001) for cognition, 0.21 (P =
0.02) for function, and 0.23 (P = 0.010) for global status
(all LOCF; see Figure 2a). OC analyses produced similar
results for statistical significance and standardised effect
sizes. There was no sign of heterogeneity in either
LOCF or OC analyses.
Treatment with memantine added to donepezil was also
associated with significant clinical benefits in the MOD
subgroup. The overall standardised effect sizes for mem-
antine versus placebo were: 0.28 (P = 0.008) for cognition,
0.21 (P = 0.04) for function, and 0.28 (P = 0.008) for global
status (all LOCF; see Figure 2b). In OC analyses, meman-
tine treatment was associated with statistical significance
only for the global status measure, but similar overall stan-
dardised effect sizes were observed. There was no sign of
heterogeneity in either LOCF or OC analyses.
Efficacy in reducing the occurrence of marked clinical
worsening
In the MOD-SEV subgroup, 23/263 patients receiving
memantine added to donepezil (8.7%) showed marked
clinical worsening compared to 50/245 patients receiving
placebo added to donepezil (20.4%), a significant difference
of 11.7% (P = 0.0002; LOCF) (Figure 3a). The OC analysis
produced a similar result (8.5% versus 18.9%; P = 0.003).
In the MOD subgroup, 11/185 patients receiving mem-
antine added to donepezil (5.9%) showed marked clinical
worsening compared to 27/180 patients receiving placebo
added to donepezil (15.0%), a significant difference of 9.1%
(P = 0.006; LOCF) (Figure 3b). Again, the OC analysis pro-
duced a similar result (5.9% versus 12.6%; P = 0.047).
Safety and tolerability - incidence of adverse events
The incidence of AEs over 24 weeks was similar between
the patients treated with memantine added to donepezil
versus placebo added to donepezil (Table 3). In the
MOD-SEV subgroup, the most common AEs with an
incidence ≥ 5% in patients treated with memantine added
to donepezil were: dizziness, agitation, confusional state,
diarrhoea, and nasopharyngitis (Table 3). In the MOD
subgroup, the most common AEs with an incidence ≥ 5%
in patients treated with memantine added to donepezil
were: dizziness, diarrhoea, falls, and urinary tract infec-
tion (Table 3). In both severity subgroups, the frequency
of agitation was statistically significantly lower in patients
treated with memantine added to donepezil compared
with patients treated with placebo added to donepezil
(Table 3). There were no other statistically significant dif-
ferences between treatment groups for AEs with an inci-
dence ≥ 5%.
Discussion
Efficacy
This study combined efficacy data for 510 patients with
AD and MMSE < 20 from the two 24-week, phase III
RCTs of memantine 20 mg/day added to stable donepezil
(MEM-MD-02 and MEM-MD-12). It yielded SMD effect
sizes in favour of combination treatment with memantine
added to stable donepezil (versus placebo added to stable
donepezil) that were in the clinically significant 0.2 to 0.4
range for all efficacy domains (Figure 2).
Study MEM-MD-02, which observed significant benefits
for memantine over placebo in cognition, function, and
global status, considered generally the same population of
patients as the present study (MMSE 5 to 14, receiving
stable donepezil therapy) [16,28,29]. Consequently, the
data from MEM-MD-02 contributed favourably to the
results of this meta-analysis. Regarding study MEM-MD-
12 [17], only the data for the patients with moderate AD
and who were taking donepezil 10 mg/day were included.
Table 1 Baseline patient demographics and MMSE scores (ITT set)
MOD-SEV subgroup
a MOD subgroup
b
Characteristic Memantine added to
donepezil
(n = 264)
Placebo added to
donepezil
(n = 246)
Memantine added to
donepezil
(n = 186)
Placebo added to
donepezil
(n = 181)
Female 155 (58.7) 151 (61.4) 114 (61.3) 110 (60.8)
Age, mean (SD) years 75.1 (8.5) 75.8 (8.5) 75.9 (8.4) 76.4 (8.2)
Caucasian 236 (89.4) 230 (93.5) 166 (89.2) 171 (94.5)
Black 10 (3.8) 6 (2.4) 5 (2.7) 4 (2.2)
Asian 3 (1.1) 1 (0.4) 3 (1.6) 1 (0.6)
Other 15 (5.7) 9 (3.7) 12 (6.5) 5 (2.8)
MMSE score, mean
(SD)
11.9 (3.9) 11.7 (3.7) 13.9 (2.5) 13.4 (2.6)
Data are number (%) unless otherwise specified.
aModerate to severe Alzheimer’s disease (AD) (MMSE 5 to 19 at baseline), receiving donepezil (10 mg/day).
bModerate AD (MMSE 10 to 19 at baseline), receiving donepezil (10 mg/day). MMSE, Mini-Mental State Examination; ITT, intention-to-treat.
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function and global status of similar magnitude to those
observed for patients in MEM-MD-02 were observed;
these data demonstrated statistical significance when com-
bined in this meta-analysis with data from the MEM-MD-
02 study. These results support the hypothesis that low
power and heterogeneities due to baseline ChEI treatment
and disease severity may have significantly contributed to
the apparently divergent results previously observed
between the studies MEM-MD-02 and MEM-MD-12;
these differences may have obscured the significant bene-
fits of adding memantine to stable donepezil treatment in
patients with moderate AD.
The results observed in these meta-analyses are compar-
able to those reported in previous meta-analyses for the
Table 2 Baseline characteristics of patients excluded due
to any reason
a
All excluded patients
Characteristic Memantine
(n = 156)
Placebo
(n = 171)
Female 91 (58.3) 92 (53.8)
Age, mean (SD) years 75.4 (7.3) 75.7 (8.7)
Caucasian 147 (94.2) 162 (94.7)
Black 4 (2.6) 3 (1.8)
Asian 0 (0.0) 1 (0.6)
Other 5 (3.2) 5 (2.9)
MMSE score, mean (SD) 17.9 (4.0) 18.0 (3.6)
Data are number (%) unless otherwise specified.
aExclusion criteria were mild
Alzheimer’s disease (MMSE ≥ 20 at baseline), receiving a cholinesterase
inhibitor other than donepezil, or receiving donepezil at a dose < 10 mg/day.
MMSE, Mini-Mental State Examination.
Figure 2 Meta-analyses of change from baseline to endpoint in individual domains of Alzheimer’s disease (LOCF analysis).
aModerate
to severe (AD) (MMSE 5 to 19 at baseline), receiving donepezil (10 mg/day).
bModerate AD (MMSE 10 to 19 at baseline), receiving donepezil (10
mg/day). AD, Alzheimer’s disease; ITT, intention-to-treat; LOCF, last observation carried forward; SMD, standardised mean difference; SIB, Severe
Impairment Battery; ADAS-Cog, AD Assessment Scale-cognitive subscale; ADCS-ADL19/23, 19-/23-item AD Cooperative Study-Activities of Daily
Living scale; CIBIC-Plus, Clinician’s Interview-Based Impression of Change Plus Caregiver Input.
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The overall standardised effect sizes in the cognitive
domain are 0.36 in the present analysis (MOD-SEV sub-
group; LOCF), 0.26 in Winblad et al. (OC) [30] and 0.29
in Doody et al. (LOCF) [31]. Results found here are also
comparable to previous findings in the domains of func-
tion and global status [30,31]. A major difference between
this study and those previously reported is that patients in
the present analysis were already receiving symptomatic
benefits from donepezil, and thus the benefits observed for
Figure 3 Proportion of patients showing marked clinical worsening (ITT set, LOCF analysis).
aModerate to severe AD (MMSE 5 to 19 at
baseline), receiving donepezil (10 mg/day).
bModerate AD (MMSE 10 to 19 at baseline), receiving donepezil (10 mg/day). *P < 0.01 versus
placebo added to donepezil; **P < 0.001 versus placebo added to donepezil. AD, Alzheimer’s disease; ITT, intention-to-treat; LOCF, last
observation carried forward.
Table 3 Adverse events with an incidence ≥ 5% in either treatment group over 24 weeks (APT set)
MOD-SEV subgroup
a MOD subgroup
b
Adverse event Memantine added to
donepezil
(n = 269)
Placebo added to
donepezil
(n = 251)
Memantine added to
donepezil
(n = 190)
Placebo added to
donepezil
(n = 185)
Patients with AEs 206 (76.6) 186 (74.1) 144 (75.8) 136 (73.5)
Dizziness 20 (7.4) 19 (7.6) 17 (8.9) 16 (8.6)
Agitation 17 (6.3)* 29 (11.6) 9 (4.7)* 19 (10.3)
Confusional state 15 (5.6) 6 (2.4) - -
Diarrhoea 14 (5.2) 21 (8.4) 12 (6.3) 14 (7.6)
Nasopharyngitis 14 (5.2) 6 (2.4) - -
Falls 11 (4.1) 15 (6.0) 10 (5.3) 11 (5.9)
Urinary tract
infection
- - 10 (5.3) 8 (4.3)
Depression - - 6 (3.2) 11 (5.9)
Data are number (%).
aModerate to severe AD (MMSE 5 to 19 at baseline), receiving donepezil (10 mg/day).
bModerate AD (MMSE 10 to 19 at baseline), receiving
donepezil (10 mg/day). *P < 0.05 versus placebo added to donepezil. APT, all-patients-treated; AE, adverse event; ‘-’ denotes AEs with an incidence < 5% in both
treatment groups in the respective severity subgroup.
Atri et al. Alzheimer’s Research & Therapy 2013, 5:6
http://alzres.com/content/5/1/6
Page 7 of 11memantine treatment here are over and above those pro-
duced by donepezil alone. Also notable is that LOCF ana-
lyses yielded statistical significance for all domain
measures (cognition, function, global status), analyses (effi-
cacy in individual domains, marked clinical worsening),
and groups/subgroups (MOD-SEV, MOD) (eight out of
eight LOCF comparisons favoured combination therapy at
P < 0.05), whereas OC analyses yielded statistical signifi-
cance (P < 0.05) favouring combination therapy in six of
eight analyses (the exceptions being cognition and func-
tion in the MOD subgroup). Nonetheless, the effect size
estimates for the magnitude of clinical effects using LOCF
and OC analyses were similar, and favoured combination
therapy in each case. Taken together with the observation
that the MOD subgroup contains only approximately two-
thirds the sample size of the MOD-SEV group, and would
therefore be more sensitive to the adverse effects of reduc-
tions in power from an OC analysis (compared to an
LOCF analysis), these observations further support the
hypothesis that lack of power, along with differences in
baseline severity and ChEI type, substantially contributed
to the absence of significant findings in the original MEM-
MD-12 study.
While longer-term observational clinical cohort studies
also support the clinical effectiveness of combination
therapy above and beyond stable ChEI monotherapy
[32-34], the recently published 52-week, randomised, pla-
cebo-controlled DOMINO-AD study in patients with
moderate to severe AD (mean baseline standardised
MMSE = 9.1), receiving stable donepezil therapy for at
least 6 weeks, and whose clinician was considering a
change in drug treatment, did not report similar effects
[35]. This was an important study that had substantial
methodological limitations, which may have particularly
affected reliability and validity of results regarding detect-
ing potential group differences over the full course of the
52-week study; these limitations included a study re-
design due to delayed and insufficient recruitment,
subsequently not meeting re-adjusted sample size
requirements, high and imbalanced attrition causing
non-ignorable missing data, and reporting of mixed
effects modelling results based on difference testing, as
opposed to equivalence testing, performed without a pos-
teriori power analysis (when required sample sizes were
not achieved). Overall, these limitations may have sub-
stantially biased towards null results and resulted in
inadequate power to demonstrate significant differences
between groups, particularly between donepezil mono-
therapy and memantine added to donepezil. Yet, despite
these limitations, the overall results provide further evi-
dence to support the benefits of donepezil continuation,
and of memantine treatment despite discontinuation of
donepezil. Though controversial and open to interpreta-
tion, potential signals of efficacy for the addition of
memantine to donepezil therapy, as reflected in the initial
30 weeks of the study (during which the patient numbers
were much higher compared to week 52 assessment),
and in the behavioural domain, have been postulated by
other researchers, or reported in the study, and warrant
further secondary analysis [35,36]. Additionally, while
scientific, methodological and practical considerations
preclude direct comparison or inclusion of DOMINO-
AD data in the current study, which was designed to
assess a different hypothesis, this would be of great future
interest in a suitably designed study that would broaden
generalisability of findings to a wider and more heteroge-
neous patient population across two continents.
Long-term observational clinical cohort studies per-
formed in naturalistic settings with prospectively col-
lected data show similar patterns to RCTs, and
demonstrate Level II grade, generalisable evidence that
favours combination treatment over monotherapy, and
monotherapy over placebo/no anti-dementia medication
treatment [32-34]. Long-term combination therapy with
memantine added to a ChEI has, in the clinical setting,
been observed to significantly reduce cognitive and
functional decline, and to delay time to nursing home
admission compared to ChEI monotherapy and to
standard care without a ChEI or memantine [32,33].
Furthermore, the benefits of combination therapy
increase with time on treatment, and are sustained for
years [32]. The latter observation is further supported
by Rountree and colleagues who found that benefits of
treatment with a ChEI and/or memantine significantly
increased with treatment persistence and were observa-
ble across multiple symptom domains and stages of dis-
ease, including moderate and severe AD [37]. Finally,
the recent REAL.FR cohort study, which followed 686
patients with mild to moderate AD in 16 specialised
memory clinics in France (89% used ChEI monotherapy
at baseline, 26% used ChEI and memantine combination
therapy by year 4), reported significantly less decline in
this cohort over 4 years compared to untreated histori-
cal cohorts [38].
Clinical worsening
In the MOD-SEV subgroup, the occurrence of marked
clinical worsening in patients receiving memantine added
to donepezil was less than half that of those receiving pla-
cebo added to donepezil (8.5% versus 18.9%; P = 0.003;
OC; MMSE 5 to 19). This rate is similar to the rate
reported in patients receiving any concurrent ChEI (done-
pezil, galantamine, or rivastigmine) previously reported in
a pooled clinical worsening analysis using data from the
same two studies (9.8% versus 18.3%; P < 0.01; OC;
MMSE 5 to 19) [6]. In the present study, the occurrence
of marked clinical worsening in the MOD subgroup was
also observed to be less than half for those treated with
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donepezil.
Previous reports have considered the occurrence of clin-
ical worsening in memantine and donepezil monotherapy
studies [6,13]. In data pooled from four memantine mono-
therapy studies, a significantly lower occurrence of marked
clinical worsening was observed for memantine versus pla-
cebo (11.4% versus 23.0%; OC; week 24/28; P < 0.001;
MMSE < 20) [6]. In data pooled from three donepezil
monotherapy studies, a significantly lower occurrence of
any worsening (any concurrent decline in cognition, func-
tion, and global status) was observed for donepezil versus
placebo (14.4% versus 30.9%; OC; week 24; P < 0.0001;
MMSE 10 to 17) [13].
Though improvement is most desirable, in practice,
patients and caregivers accept that no worsening is also
an acceptable outcome [1]. Patients with AD benefit
from stabilised symptoms, as they are able to remain at a
higher functional level for longer [1]. Caregivers also ben-
efit from reduced patient decline as the patient’sr e t a i n e d
independence reduces the burden placed upon the care-
giver. In the present study, since patients in the placebo
group were already receiving stable donepezil treatment,
the addition of memantine offered extra benefits by
further reducing the occurrence of marked clinical wor-
sening, not just in later stages, but also in moderate AD.
Safety and tolerability
In moderate to severe AD, and moderate AD, combina-
tion treatment with memantine and donepezil was well-
tolerated and had a similar incidence of AEs as treatment
with placebo added to donepezil. Individually, studies
MEM-MD-02 and MEM-MD-12 indicated that combina-
tion therapy with memantine added to donepezil/ChEI
was safe and well-tolerated [16,17], a pattern of safety
that was also recently reported in the DOMINO-AD
study [35]. In the present study, the frequency of agita-
tion was approximately half in the memantine-treated
group compared with the placebo-treated group. A sig-
nificant reduction in the incidence of agitation in favour
of memantine monotherapy over placebo has been pre-
viously observed in a meta-analysis of patients with AD
[31]. Furthermore, in a pooled analysis of patients with
moderately severe to severe AD (MMSE 3 to 14) who
had baseline symptoms of agitation/aggression or psy-
chosis, a significantly greater proportion of memantine-
treated patients experienced an improvement of agita-
tion/aggression over 6 months than patients treated with
placebo [39]. AE profiles from previous studies also sug-
gest that memantine administration may be associated
with amelioration of gastrointestinal AEs typically asso-
ciated with ChEI use, and that rates of diarrhoea and fae-
cal incontinence may be reduced when memantine is
added to stable donepezil treatment [16,40].
Strengths of study
This study includes data from rigorous 24-week RCTs in
the largest population of moderate to severe patients trea-
ted with the combination of memantine/placebo added to
donepezil considered to date (510 participants in the ITT
set). The two studies included in the meta-analyses had
similar inclusion/exclusion criteria, and by further restrict-
ing the MMSE range to 5 to 19 and the allowed baseline
ChEI to donepezil 10 mg/day, the subjects included pro-
duced much more homogeneous groups of patients in
which potential signals of efficacy could be detected. Calcu-
lation of effect sizes in this study also allows for compari-
sons within and between studies and to gauge the
magnitude of clinical effects/clinical significance, not just
statistical significance. Measuring marked clinical deteriora-
tion by combining three efficacy scales provides a powerful
tool for clinicians to determine whether the patient’sc o n d i -
tion as a whole is deteriorating; a real and clinically signifi-
cant deterioration that is likely to be the result of true
disease progression rather than minor or statistical fluctua-
tions that may be observed in any single domain [6].
Finally, expected treatment-related benefits must be
balanced with potential treatment-related risks to provide
an informed picture of the risk-benefit calculus of the treat-
ment paradigm to patients and caregivers; this study
presents the largest safety and AE data profile specifically
available for the combination of memantine added to done-
pezil in moderate, as well as for moderate to severe AD.
Limitations of study
Only two 24-week phase III RCTs met inclusion criteria
and could thus be included, and only a subgroup of the
patients from each study was included, for the reasons
discussed. Also, while the MMSE has been commonly
used as a disease stage proxy to determine patient inclu-
sion in clinical trials, it only measures cognition, which is
just one of several AD symptom domains, and it does so
in a very limited way. The present study used MMSE in
the same manner, and is thus subject to these same lim-
itations. However, this does allow application of these
results to the same criteria and populations identified by
funding groups or agencies that provide treatment guide-
lines for the use or reimbursement of AD medications.
Furthermore, measuring marked clinical worsening as
defined in this study, may not capture significant decline
in all patients, as a patient may largely deteriorate in one
domain and yet not be considered to have marked clini-
cal worsening; it is therefore a conservative estimate [6].
Finally, limiting data inclusion criteria in this study to
test an a priori hypothesis leverages patient homogeneity,
and likely lowers the odds of variability in study mea-
sures, thereby increasing the internal validity of the
results, but at the cost of potentially decreasing external
validity and generalisability of results to the wider and
Atri et al. Alzheimer’s Research & Therapy 2013, 5:6
http://alzres.com/content/5/1/6
Page 9 of 11more heterogeneous non-research AD patient popula-
tion; particularly the generalisability of results to those
patients who are in milder clinical stages, are treated
with ChEIs other than donepezil (that is, patients treated
with galantamine or rivastigmine), or are enrolled in pri-
marily non-research clinical settings. In clinical practice,
patients are also often treated for much longer than the
limited 24-week duration studied in these phase III
RCTs. This has been emphasised to argue that Level II
grade evidence from long-term observational clinical
cohort studies should be used to complement and inform
clinicians and researchers in the process of therapeutic
discovery and assessment, as well as in determining and
monitoring the long-term risk-benefit calculus of thera-
pies to patients and to society [34].
Conclusions
The addition of memantine to patients’ ChEI therapy when
they reach the moderate stage of AD has important practi-
cal relevance. The results presented in this study provide
evidence in a large RCT meta-analysis population, for the
significant benefits of the addition of memantine to stable
donepezil therapy in moderate, as well as moderate to
severe AD. These results, along with the wealth of other
clinical evidence [34,41], support and extend previous find-
ings that combination treatment is associated with clini-
cally significant benefits in reducing 24-week decline in
cognition, function, global status, and the occurrence of
marked clinical worsening. In the absence of disease-modi-
fying therapies, retaining greater cognitive and functional
abilities can produce disease-course-modifying effects that
may help patients with AD remain independent for longer.
Importantly, combination therapy with memantine added
to donepezil demonstrates good safety and tolerability, and
the observed benefits are over and above those of donepezil
alone. Taken together, these results support a risk-benefit
calculus that is in favour of combination therapy with
memantine added to donepezil in moderate, as well as
moderate to severe AD, and imply translation of clinically
meaningful benefits to patients, caregivers, and society.
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